3401-57-8

Upstream product

• 3257-18-9 benzyloxycarbonyl-S-benzylcysteine 
• 107960-02-1 1,2,2,2-tetrachloroethyl-(N-succinimidyl)carbonate 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 

Downstream Products

• 75509-29-4 N-benzyloxycarbonyl-S-benzyl-L-cysteinylglycylglycine succinimido-ester 
• 75509-33-0 S-benyl-L-cysteinylglycylglycinamide 
• 75509-38-5 (R)-2-Amino-3-benzylsulfanyl-N-{[({(R)-2-benzylsulfanyl-1-[({[((R)-2-benzylsulfanyl-1-{[(carbamoylmethyl-carbamoyl)-methyl]-carbamoyl}-ethylcarbamoyl)-methyl]-carbamoyl}-methyl)-carbamoyl]-ethylcarbamoyl}-methyl)-carbamoyl]-methyl}-propionamide; hydrobromide 
• 75509-36-3 C₄₈H₆₂N₁₂O₁₂S₃ 
• 75509-37-4 N-benzyloxycarbonyl-S-benyzl-L-cysteinyldiglycyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-cysteinylglycylglycinamide 
• 75509-35-2 (R)-2-Amino-3-benzylsulfanyl-N-({[((R)-2-benzylsulfanyl-1-{[(carbamoylmethyl-carbamoyl)-methyl]-carbamoyl}-ethylcarbamoyl)-methyl]-carbamoyl}-methyl)-propionamide; hydrobromide 
• 65710-06-7 (R)-2-[2-(2-Acetylamino-acetylamino)-acetylamino]-3-benzylsulfanyl-N-({[((R)-2-benzylsulfanyl-1-{[(carbamoylmethyl-carbamoyl)-methyl]-carbamoyl}-ethylcarbamoyl)-methyl]-carbamoyl}-methyl)-propionamide 
• 75509-34-1 N-benzyloxycarbonyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinylglycylglycinamid 
• 75509-32-9 N-acetyldiglycyl-S-benzyl-L-cysteinylglycylglycinamide 
• 75509-41-0 C₅₆H₇₁N₁₃O₁₂S₄*BrH 
• 75509-39-6 N-acetyldiglycyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinylglycylglycinamide 
• 75509-40-9 N-benzyloxycarbonyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinyldiglycyl-S-benzyl-L-cysteinylglycylglycinamide 
• 77374-57-3 Z-Cys(Bzl)-Gly₃-Cys(Bzl)-Gly₃-Cys(Bzl)-Gly₂-NH₂ 
• 77374-51-7 Ac-Gly₂-Cys(Bzl)-Gly₂-Cys(Bzl)-Gly₃-Cys(Bzl)-Gly₂-NH₂ 

Relevant academic research and scientific papers

Structure-Activity Study of 5-Substituted 1-Carbobenzoxy-2-iminohydantoins as Potential Anticonvulsant Agents

On the basis of our previous findings, a series of 5-substituted 2-iminohydantoins has been synthesized and tested for anticonvulsant activity to better understand the SAR of 2-iminohydantoins.Among the compounds tested, (S)-(+)-1-carbobenzoxy-2-iminohydantoin analogs with ethyl (6)-, n-propyl (7a)-, isopropyl (8)-, allyl (9)-, and sec-butyl (11)-substituted groups at the C5 of the iminohydanotin ring provided the best activities against the MES test with ED50 values in the range of 52-74 mg/kg.All of the above compounds except 8 also showed activity against the scMET test with ED50 values in the range of 141-223 mg/kg.All significantly active compounds (1, 6, 7a, 8, 9, and 11) possesed aliphatic hydrocarbon side chains of two- to three-carbon lengths at the C5 position.All of the compounds with no or minimal activity had either shorter or longer side chains.The compounds substituted at the C5 position by aryl groups, arylalkyl groups, or alkyl and arylalkyl groups containing heteroatoms also showed no activity against the MES and scMET tests.The results suggested that the C5 side chain with the correct stereochemistry in 2-iminohydantoins provides optimal anticonvulsant activity when the side chains are aliphatic hydrocarbons with a lenght, ignoring branchingg, of two to three carbons.

Novel Preparation of N-Protected Amino Acid Active Esters Using 1,2,2,2-Tetrachloroethyl Carbonates

1,2,2,2-Tetrachloroethyl chloroformate reacts with substituted phenols or N-hydroxy imides to yield crystalline and stable mixed aryl or oximido tetrachloroethyl carbonates.When allowed to react with an N-protected amino acid derivative, these compounds proved to be efficient for the syntheses of the corresponding active esters.A series of active esters including p-nitrophenol, trichlorophenol, pentafluorophenol, and N-hydroxysuccinimide derivatives were prepared by this new procedure.